2024-03-29T13:23:51Zhttp://ginmu.naramed-u.ac.jp/dspace-oai/request
oai:ginmu.naramed-u.ac.jp:10564/20832017-05-29T06:09:49Zhdl_10564_2082Development of a web-based survey for monitoring daily health and its application in an epidemiological surveySugiura, HiroakiOhkusa, YasushiAkahane, ManabuSano, TomomiOkabe, NobuhikoImamura, Tomoakiweb-based surveysyndromic surveillancelong-term operationBackground: Early detection of symptoms arising from exposure to pathogens, harmful substances, or environmental changes requires timely intervention. The administration of web-based questionnaires is a potential method for collecting information from a sample population.
Objective: To develop a web-based daily questionnaire for health (WDQH) for symptomatic surveillance.
Methods: We adopted two different survey methods to develop the WDQH: an internet panel survey, which included subjects already registered with an internet survey company, and the Tokyo Consumers’ Co-operative Union (TCCU) internet survey, in cooperation with the Japanese Consumers’ Co-operative Union, which recruited participants by website advertising. The internet panel survey participants were given a fee everyday for answers, and the survey was repeated twice with modified surveys and collection methods; Internet Panel Survey I was conducted every day, and Internet Panel Survey II was conducted every 3 days to reduce costs. We examined whether the survey remained valid by reporting health conditions on day 1 over a 3-day period, and whether the response rate would vary among groups with different incentives. In the TCCU survey, participants were given a fee only for initial registering, and health information was provided in return for survey completion. The WDQH included the demographic details of participants and prompted subjects to answer questions about the presence of various symptoms by e-mail. Health information collected by the WDQH was then used for the syndromic surveillance of infection.
Results: Response rates averaged 47.3% for Internet Panel Survey I, 42.7% for Internet Panel Survey II, and 40.1% for the TCCU survey. During a seasonal influenza epidemic, a rapid increase in the number of patients with fever was reported by the WDQH using the early aberration reporting system.
Conclusions: We developed a health observation method based on self-reporting by subjects via the internet. We validated the usefulness of the WDQH via its practical use in syndromic surveillance.博士(医学)・甲第581号・平成24年3月16日The definitive version is available at "http://www.jmir.org/2011/3/e66/"JMIR Publications2012-03-26T05:18:37Z2012-03-26T05:18:37Z2011-09-23ThesisThesis or Dissertation389120 bytesapplication/mswordJournal of medical Internet research 2011 (Sep 23); 13(3):e6614388871http://hdl.handle.net/10564/208314388871Journal of medical Internet research133e66enghttp://www.ncbi.nlm.nih.gov/pubmed/21946004http://dx.doi.org/10.2196/jmir.1872author
oai:ginmu.naramed-u.ac.jp:10564/21032017-06-30T03:44:43Zhdl_10564_2082Olmesartan inhibits angiotensin II-induced migration of vascular smooth muscle cells through Src and MAP kinase pathwaysアンジオテンシンⅡによるSrc及びmitogen-activated protein kinaseを介した血管平滑筋細胞の遊走に対するオルメサルタンの阻害作用Kyotani, YojiZhao, JingTomita, SayukoNakayama, HitoshiIsosaki, MinoruUno, MasayukiYoshizumi, Masanoriangiotensin IIangiotensin receptor blockerARBolmesartancell migrationClinical studies have shown that Angiotensin receptor blockers (ARBs) reduce the risk of cardiovascular diseases in hypertensive patients. It is assumed that the reduction of the risk by ARBs may be attributed in part to the inhibition of AII-induced vascular smooth muscle cell (VSMC) migration associated with atherosclerosis. However, the effect of ARBs on AII-induced changes in intracellular signaling and resultant cell migration has not been well established. Here, we investigated the effect of olmesartan, an ARB, on AII-induced extracellular signal-regulated kinases 1/2 (ERK1/2) and c-Jun N-terminal kinase (JNK) activation and rat aortic smooth muscle cell (RASMC) migration. Olmesartan inhibited AII-induced ERK1/2 and JNK activation at lower concentrations (10 nM). On the other hand, PP2, an Src tyrosine kinase inhibitor, also inhibited AII-induced ERK1/2 and JNK activation, but its effect on ERK1/2 was less pronounced than that of olmesartan. Olmesartan, U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and PP2 potently inhibited AII-induced RASMC migration. From these findings, it was inferred that angiotensin receptor blockade by olmesartan results in the inhibition of AII-induced activation of Src, ERK1/2, and JNK in RASMC. Olmesartan may be a potent inhibitor of AII-induced VSMC migration, which may be involved in the progression in atherosclerosis.博士(医学)・甲第584号・平成24年3月16日The definitive version is available at "http://dx.doi.org/10.1254/jphs.09332FP"公益社団法人日本薬理学会2012-03-30T07:20:09Z2012-03-30T07:20:09Z2010-05ThesisThesis or Dissertation231607 bytes181443 bytesapplication/pdfapplication/pdfJournal of Pharmacological Sciences Vol. 113 (2010) , No. 2 pp.161-16813478613http://hdl.handle.net/10564/210313478613AA11806667Journal of Pharmacological Sciences1132161168enghttp://www.ncbi.nlm.nih.gov/pubmed/20508392http://dx.doi.org/10.1254/jphs.09332FPauthor